Evaluation and treatment of older-age bipolar disorder: a narrative review

Rajesh R Tampi1,2,3, Pallavi Joshi3, Gargi Bhattacharya4, Sheila Gupta5

1Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH, USA; 2Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; 3Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 4Department of Electrical and Computer Engineering, Purdue University, West Lafayette, IN, USA; 5Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, Buffalo NY, USA

Abstract

Objectives: This narrative review aims to synthesize information from the literature regarding older-age bipolar disorder (OABD) in order to provide up-to-date information on this important illness.

Methods: We searched Ovid (Medline, Embase and PsychInfo) on October 1, 2020, using the keywords “bipolar disorder”, “older adults” and “elderly” to identify relevant articles on OABD. Additionally, the bibliography of identified articles was reviewed for pertinent studies.

Discussions: OABD is a term that is used to describe bipolar disorder (BD) occurring amongst individuals ≥50 years of age. Evidence indicates that OABD accounts for a quarter of all cases of BD. When compared to individuals with early-onset BD, individuals with OABD have a greater association with cerebrovascular disease and other neurological disorders, less family history of mood disorders, and utilize almost four times the total amount of mental health services. In addition, they are four times more likely to have psychiatric hospitalizations when compared to age-matched controls. Despite a dearth of controlled studies on the use of pharmacotherapy amongst individuals with OABD, available evidence from mixed-age studies indicates the efficacy of commonly used medications in individuals with early-onset BD. Additionally, psychosocial treatments have been found to be effective as adjunctive management strategies amongst individuals with OABD. Furthermore, electroconvulsive therapy may be effective in the treatment of refractory cases of OABD.

Conclusions: There is a great need for an improved understanding of the phenomenology and neurobiology of OABD. Additionally, research into effective treatments for this serious psychiatric disorder will mitigate the suffering of individuals with OABD.

Keywords: antipsychotics, bipolar disorder, early-onset bipolar disorder, electroconvulsive therapy, lithium, mood stabilizers, older-age bipolar disorder, psychosocial treatments.

Citation

Tampi RR, Joshi P, Bhattacharya G, Gupta S. Evaluation and treatment of older-age bipolar disorder: a narrative review. Drugs in Context 2021; 10: 2021-1-8. DOI: 10.7573/dic.2021-1-8

Introduction

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), describes bipolar disorder (BD) as an illness characterized by recurring episodes of mania or hypomania and depression. The bipolar and related disorders chapter in the DSM-5 describes bipolar I disorder (BD-I) and bipolar II disorder (BD-II) as the two major subtypes of BD. BD-I is diagnosed when individuals who meet the criteria for a manic episode also report major depressive episodes sometime during the course of their life. BD-II is diagnosed when individuals report at least one episode of major depression and at least one hypomanic episode during their lifetime. Other diagnoses that are included in the bipolar and related disorders chapter are the cyclothymic disorder, substance or medication-induced bipolar and related disorder, bipolar and related disorder due to another medical condition, other specified bipolar and related disorder, and unspecified bipolar and related disorder. In this review, we focus only on BD-I and BD-II.

Although not as common as amongst younger adults, BD can occur amongst older adults. Available evidence indicates that the number of individuals with older-age BD (OABD) is expected to increase significantly over the next few decades. Available evidence indicates that the relative frequency of OABD had increased from 1% to 11% between 1980 and
In this review, we describe the various aspects of OABD, including the evidence-based treatment for this disorder.

**Methods**

The principal author (RRT) searched Ovid [Medline (1946-), Embase (1974-) and PsychInfo (1806-)] on October 1, 2020, using the keywords "bipolar disorder and older adults" and "bipolar disorder and elderly" to identify relevant articles on OABD. The initial search for studies was not restricted by the language of publication of the study. However, in the final analysis, we only included studies involving human patients published in English language journals or with official English translations. In addition, the bibliography of identified articles was reviewed for pertinent studies. PRISMA guidelines were not followed as this article was intended as a narrative review and not a systematic review.

A review of abstracts and the removal of all duplicates, a total of 310 articles were initially identified. The author selected a total of 63 articles that provided the core information regarding OABD for full-text review. An additional 25 articles were included to provide general information regarding BD and to also provide important information regarding topics like suicide and risk for death with antipsychotics. The core articles were selected irrespective of the type of study (randomized controlled trials (RCTs), meta-analysis, systematic reviews, scoping reviews, narrative reviews, etc.) if they provided relevant information regarding the epidemiology, neurobiology, assessment and treatment of individuals with OABD.

**Review**

**Epidemiology**

According to the International Society for Bipolar Disorders, Task Force OABD is defined as BD that occurs amongst individuals ≥50 years of age. Available evidence indicates that approximately 25% of all cases of BD occur amongst individuals aged ≥60 years, with >10% occurring amongst individuals aged ≥70 years.

The point prevalence of OABD is between 0.1% and 0.5%, with a lifetime prevalence of 0.5–1.0%. Additionally, 10–25% of all older adults who are diagnosed with a mood disorder have BD. It is estimated that approximately 10% of individuals with OABD develop their first-onset mania episode in association with a neurovascular disorder. Approximately 6% of all geriatric psychiatry outpatient visits and 8–10% of all geriatric inpatient admissions involve individuals with OABD. Individuals with OABD account for approximately 25% of all cases of BD occurring amongst individuals aged ≥60 years, with >10% occurring amongst individuals aged ≥70 years.

A greater association with cerebrovascular disease and other neurological disorders is seen amongst individuals with OABD when compared to individuals with EOBD. Manic episodes are often associated with vascular changes in the right cerebral hemisphere amongst these individuals, whereas vascular lesions in the left cerebral hemisphere are associated with depressive symptoms.

It has been noted that individuals with OABD tend to have, on average, three to four medical comorbidities. Common comorbidities include metabolic syndrome, respiratory and cardiovascular diseases, and endocrine disorders. These comorbidities appear to worsen outcomes amongst individuals with OABD, including increasing the rates for suicide. The rates of comorbidities appear to be similar amongst individuals with OABD and age-matched controls.

Neuroimaging studies indicate that individuals with OABD have greater structural abnormalities in the brain when compared to individuals with EOBD. These include a greater amount of white-matter hyperintensities especially in the frontal, parietal and putaminal areas of the brain. Some studies indicate that there is greater cortical sulcal widening and lateral ventricle-brain ratio scores amongst individuals with OABD when compared to individuals with EOBD, although the majority of studies indicate no significant difference in grey matter, white matter and total brain volumes amongst these individuals.

Psychiatric comorbidities have been found to be common amongst individuals with OABD when compared to age-matched controls, but these rates are lower than what is noted amongst individuals with EOBD. Common comorbidities include alcohol use disorder (12-month and lifetime prevalence rates, 38.1% and 38.1%, respectively), dysthymia (12-month and lifetime prevalence rates, 7.1% and 15.5%, respectively), generalized anxiety disorder (12-month and lifetime prevalence rates, 9.5% and 20.5%, respectively) and panic disorder (12-month and lifetime prevalence rates, 11.9% and 19.0%, respectively). A higher prevalence of alcohol use/alcohol use disorder is seen in men with OABD, whereas women have a
greater prevalence of panic disorder when compared to age-matched controls. Psychotic symptoms appear to occur at a similar rate amongst individuals with OABD when compared to individuals with EOBD.11

Available evidence indicates that older adults are at greater risk for suicide when compared to younger adults.10 The rates of suicide are higher amongst older men when compared to older women. Known risk factors for suicide amongst older adults include the presence of a psychiatric disorder, having chronic illnesses and disabilities, bereavement and social isolation, and a history of non-fatal self-harm. It has also been noted that suicide attempts amongst older adults are often of greater determination and lethality. A population-based case-control study of individuals aged ≥66 years from Canada found that, amongst the psychiatric disorders that are associated with completed suicide, the odds ratio (OR) for suicide was highest for BP (OR, 9.20) followed by depression (OR, 6.44), psychotic disorders (OR, 5.09) and anxiety disorders (OR, 4.65).22 In this study, death by firearms was the most frequent method for suicide amongst men and self-poisoning was the most frequent method amongst women. It was noted that the majority of individuals who committed suicide had been evaluated by a physician in the month prior to their death when compared to controls (75% versus 49%; p<0.001). Additionally, 75% of these individuals were registered for more than three visits with their physician. Furthermore, individuals who committed suicide visited a psychiatrist more often in the preceding week when compared to controls (6% versus 0.2%; p<0.001).

Available evidence indicates that individuals with OABD, when compared to age-matched controls, have been found to have lower scores on a variety of cognitive screening tools, including the Mini-Mental State Examination (MMSE) (p=0.0007) and the Mattis Dementia Rating Scale (DRS) (p=0.0003) after adjusting for age and education.31 However, there was no correlation noted between the MMSE score (Pearson r=0.07) or total DRS score (r=0.20) and the Young Mania Rating Scale (YMRS) scores. When compared to individuals with EOBD, individuals with OABD have been found to be more impaired on word fluency, mental flexibility and psychomotor performance, but these impairments were not attributable to age, education or cerebrovascular risk factors.32 When compared to age-matched and education-matched controls, approximately half of euthymic individuals with OABD had a score ≥1 standard deviation (SD) below the mean on the MMSE and the DRS and 1–2 SD below the mean on executive functioning.31 Amongst individuals with OABD, a greater number of vascular risk factors and hospital admissions are related to worse outcomes of cognitive functioning.34

When compared to age-matched individuals with unipolar depression, individuals with OABD have an earlier age at onset of illness, greater overall symptom severity and have been found to be more impaired with reference to living skills in the community.35 Additionally, they utilize approximately four times the total amount of mental health resources and are four times more likely to be hospitalized psychiatrically over the past 6 months when compared to age-matched individuals with unipolar depression.

A comparison between OABD and EOBD is provided in Table 1.

### Diagnosis

A definitive diagnosis of OABD can be made via a thorough history.6 The development of mood symptoms can also occur due to a comorbid medical illness, a neurological disorder and/or due to the effect of prescribed medications or illicit drugs. A focused physical examination will assist in identifying comorbid medical and/or neurological disorders that may cause instability of mood amongst older adults.8 Common conditions that cause mood fluctuations include metabolic disorders such as diabetes and/or thyroid disorders. These disorders can be identified via laboratory tests. Common tests include a

---

**Table 1. Differences between late-onset and early-onset bipolar disorder**

| Features                              | OABD                  | EOBD                  |
|---------------------------------------|-----------------------|-----------------------|
| Age of onset                          | ≥50 years             | ≤50 years             |
| Family history                        | Less likely           | More likely           |
| Presenting symptom                    | Depression            | Mania or hypomania    |
| Manic symptoms                        | Less likely           | More likely           |
| Latency between first and second episodes | Longer               | Shorter               |
| Cerebrovascular disease               | More likely           | Less likely           |
| Medical comorbidities                 | More likely           | Less likely           |
| Psychiatric comorbidities             | Less likely           | More likely           |
| Cognitive dysfunction                 | More likely           | Less likely           |
| Healthcare service utilization        | Greater use           | Lesser use            |

EOBD, early-onset bipolar disorder; OABD, older-age bipolar disorder.
REVIEW – Evaluation and treatment of older-age bipolar disorder

There are no specific rating scales developed for use amongst individuals with OABD; however, some of the scales used for EOBD can also be used for OABD. These scales can assist with the quantification and qualification of the symptoms of BD and help assess their progress. The Mood Disorder Questionnaire is a common screening tool used for the identification of BP amongst adults. Although it has good sensitivity and specificity for the detection of a lifetime history of mania or hypomania, its routine use can result in the potential over-diagnosis of BD.

Available evidence indicates that, for the detection of manic symptoms amongst individuals with OABD, the YMRS is most commonly used. For the detection of depressive symptoms, the Hamilton Depression Rating Scale (HDRS) and the Montgomery–Åsberg Depression Rating Scale (MADRS) are often used. The most commonly used clinical assessment tool amongst individuals with BD is the Structured Clinical Interview from the DSM-IV. Finally, a diagnosis of BD can be confirmed using the criteria from the DSM-5. A flow diagram for the assessment of bipolar disorder amongst older adults is provided in Figure 1.

Treatment

Psychosocial therapy

The available evidence for using specific psychotherapies for OABD is limited and often extrapolated from mixed-age studies or from anecdotal evidence. Medication adherence skills training (the MAST-BD intervention) amongst individuals with OABD has been found to improve their ability to manage medications, compliance with medications, symptoms of depression and certain domains of health-related quality of life with medium effect sizes (Cohen’s d, 0.30–0.57). A manual-based medical care model was found to improve patient satisfaction rates, dropout rates and follow-up rates amongst individuals with OABD.

Pharmacotherapy

Current evidence for pharmacotherapy for OABD is based on a limited number of clinical practice guidelines and RCTs. Efficacy has been noted for lithium, anticonvulsant

---

**Figure 1. Assessment of bipolar disorder amongst older adults.**

1. Obtain thorough history
   - (Includes course of illness, medical history, psychiatric history, current and past medications, pre-morbid personality, cognition and functional status)

2. Complete a standardized mental status examination and formal cognitive testing

3. Complete standardized assessment scales & Neuropsychological testing if needed

4. Complete a focused physical examination to rule out medical or neurological disorders

5. Order appropriate investigations
   - (Includes blood & urine examination, vitamin B12 & folate levels, RPR/VDRL, HIV testing, urine drug screen and neuroimaging studies)

6. Treat underlying medical & neurological disorders & Remove offending medications and/or drugs of abuse

---
medications, antipsychotic medications, antidepressant medications and benzodiazepines as well as for electroconvulsive therapy (ECT). Dols et al. evaluated data from 34 national and international guidelines and found that, in a majority of these guidelines, there was no specific section dedicated to the treatment of OABD. The general principles of pharmacotherapy for OABD are similar to those of individuals with EOAB albeit with the need for closer monitoring for side effects, comorbid conditions and the coprescription of medications. However, the therapeutic serum levels of lithium amongst individuals with OABD are suggested to be lower than those in individuals with EOAB, although this recommendation is not based on extensive research evidence. Below, we discuss the common pharmacotherapeutic modalities used for the treatment of individuals with OABD.

Lithium
The prototypical drug for the treatment of OABD has been lithium. Lithium appears best suited for individuals who have euphoric mania and for individuals who have minimal comorbid neurological disorders. Evidence also indicates that lithium decreases suicide risk and the risk for cognitive decline. Amongst individuals with OABD, lithium remains the drug of choice for maintenance treatment using monotherapy; the daily dose of lithium should be 25–50% of the recommended daily adult dose. Additionally, the lithium level target amongst individuals with OABD is between 0.4 and 0.7 mEq/L. Prior to starting treatment with lithium, it is recommended that thyroid, cardiac and renal functions be evaluated. Lithium appears to cause more adverse effects amongst individuals with OABD when compared to individuals with EOAB. Common adverse events noted with lithium use include cognitive impairment, oedema, gait impairment, hypothyroidism, renal dysfunction, sedation and weight gain. Lithium should be prescribed with caution amongst individuals who are also coprescribed a thiazide or loop diuretic, angiotensin-converting enzyme inhibitors, or NSAIDs. Amongst individuals with OABD, the risk for developing lithium toxicity is higher amongst those individuals who have multiple medical comorbid conditions and are coprescribed multiple medications.

Anticonvulsants
The evidence regarding the use of anticonvulsant mood stabilizers amongst individuals with OABD is limited. It has been noted that, amongst individuals with OABD, the use of valproic acid (VPA) appears to be more prevalent despite a lack of evidence that it has greater efficacy or tolerability when compared to lithium. The daily dose of VPA required to maintain levels that are therapeutic amongst individuals with OABD is lower than what would be expected for younger adults. When prescribing VPA for OABD, care must be taken as it may interact with other drugs commonly prescribed to older adults, including acetylsalicylic acid, warfarin, phenytoin and phenobarbital, thereby causing serious adverse effects.

Combining VPA with lithium may be beneficial amongst individuals with OABD in whom the symptoms are partially responsive to lithium monotherapy or amongst those individuals who present with a rapid cycling type of illness. In the first and only RCT evaluating the efficacy and tolerability of medications for OABD, the researchers compared lithium carbonate to divalproex in individuals with BP-I. They included 224 individuals aged ≥60 years who presented with a manic, hypomanic or mixed episode. The participants were randomly assigned under double-blind conditions to receive either lithium or divalproex. The targeted serum concentrations for lithium and VPA were 0.80–0.99 mEq/L and 80–99 µg/mL, respectively, for 9 weeks. Amongst those individuals who had an incomplete response to the drugs after 3 weeks, the use of open adjunctive risperidone was permitted. The investigators found that at 9 weeks, the response rates amongst the lithium and divalproex groups were not significantly different (79% and 73%, respectively). However, the response rates favoured lithium when compared to divalproex in the longitudinal mixed model. In both the lithium and divalproex groups, a similar proportion of individuals achieved the targeted concentrations of the respective drug (57% and 56%, respectively) and the need for adjunctive risperidone was low (17% and 14%, respectively). Furthermore, the rates of attrition were also similar (14% and 18% at week 3 and 51% and 44% at week 9, respectively). Additionally, there was no significant difference in the rates of sedation between the two groups. However, tremors were commonly noted in the lithium group when compared to the divalproex group.

A retrospective review that evaluated individuals aged ≥55 years with BP-I who were treated with lamotrigine, lithium or placebo, the investigators found that lamotrigine delayed the time to intervention for any mood episode and for a depressive episode when compared to placebo. Additionally, when compared to placebo, lithium delayed the time to intervention for any manic/hypomanic/mixed episode. Back pain and headaches were the most common adverse effects in the lamotrigine group. However, no rashes were reported in this group. Dyspraxia, tremors, xerostomia, headaches, infection, amnesia, dizziness, diarrhoea, nausea and fatigue were the most common adverse effects in the lithium group. It has also been noted that the cognitive profile of lamotrigine is more favourable when compared to other anticonvulsant mood stabilizers. This would be beneficial when used amongst individuals with OABD.

Current evidence does not include any RCT of carbamazepine amongst individuals with OABD. Data from mixed-age population studies indicate that carbamazepine is not as effective as lithium or VPA in the management of acute mania episodes or for maintenance treatment. Carbamazepine may be beneficial for individuals presenting with non-classical or atypical features of BD. However, due to its significant drug–drug interactions, this drug may be less well tolerated by individuals with OABD.
The routine use of gabapentin, oxcarbazepine, topiramate or zonisamide cannot be recommended amongst individuals with OABD as there are no controlled studies of these medications amongst this population.\textsuperscript{42}

**Antipsychotics**

Atypical antipsychotic medications that are approved for the treatment of BD by the FDA in the United States include aripiprazole, asenapine, olanzapine, quetiapine, quetiapine extended release, risperidone and ziprasidone.\textsuperscript{62} Additionally, olanzapine-fluoxetine combination, quetiapine and lurasidone are approved for the acute treatment of bipolar depression.\textsuperscript{63}

The use of antipsychotic medications is especially important amongst individuals with dementia, as evidence indicates that these drugs increase the risk for cerebrovascular adverse events and dementia.\textsuperscript{80}

Amongst individuals with OABD, risperidone was found to be effective in a small case series.\textsuperscript{64} An open trial found that clozapine showed efficacy in treating symptoms of mania and psychosis amongst three older institutionalized males with BD.\textsuperscript{65} These individuals were either refractory to or were unable to tolerate monotherapy or combination treatments of lithium, VPA, benzodiazepines and other antipsychotics. Symptoms showed sustained improvements at an average of 11 months and no significant reductions in the granulocyte count were noted.

A post hoc analysis of pooled data from two quetiapine monotherapy trials indicated that a dose of quetiapine 400–800 mg daily when compared to placebo resulted in significant improvements in symptoms of mania from baseline to day 21 amongst individuals with BD who were aged ≥55 years.\textsuperscript{66} Amongst these individuals, sustained improvements in mania scores were apparent by day 4 of treatment. The most common adverse effects that were noted in the quetiapine group were dry mouth, somnolence, postural hypotension, insomnia, weight gain and dizziness.

Two studies evaluated the use of asenapine amongst older adults with BD.\textsuperscript{67,68} In the first study including 11 individuals with acute bipolar mania and a mean age of 67.7 years who were consecutively admitted to a psychogeriatric unit, the use of asenapine mean dose was 11.2 mg daily, and gastrointestinal discomfort (33%) followed by restlessness (13%), tremors (13%), cognitive difficulties (13%) and sluggishness (13%) were the most common adverse effects noted amongst individuals treated with asenapine.

A post hoc analysis evaluated the use of lurasidone when compared to placebo from two RCTs amongst individuals who were aged ≥55 years with a DSM-IV-TR diagnosis of BP-I or II depression.\textsuperscript{69} The first study was a monotherapy study that compared fixed flexible doses of lurasidone 20–60 mg daily or 80–120 mg daily with placebo.\textsuperscript{70} The second study compared flexible doses of lurasidone 20–120 mg daily as adjuncts to either lithium or VPA when compared with placebo.\textsuperscript{71} In both studies, 17.4% and 15.5% of the participants were aged ≥55 years. In the first study, the lurasidone group did much better on the mean change in the MADRS total score at week 6 when compared to the placebo group (p=0.003, effect size 0.83). In the second study, the mean change on the MADRS total score at week 6 did not show any superiority for the lurasidone group when compared to the placebo group (p=0.398, effect size 0.26). The discontinuation rates due to adverse events in the lurasidone group when compared to placebo were similar in both studies (6.8% versus 6.9%) and (3.8% versus 7.1%), respectively.

Metabolic laboratory values were minimally affected by the use of lurasidone.

The FDA has a black box warning for increased mortality when antipsychotic medications are used amongst individuals with dementia.\textsuperscript{72} It is prudent to exercise caution when prescribing antipsychotic medications to older adults especially those individuals with dementia, as evidence indicates that these drugs increase the risk for cerebrovascular adverse events and deaths amongst this vulnerable group of individuals.\textsuperscript{72}

**Antidepressants**

The use of antidepressants amongst older (≥66 years) individuals with BD was found to decrease the risk of hospitalization for manic/mixed episodes (adjusted rate ratio, 0.5) but not for depressive episodes (adjusted rate ratio, 0.7) when compared to individuals in the control group, who did not receive an antidepressant during the same period in a population-based retrospective cohort study.\textsuperscript{73}

**Benzodiazepines**

Evidence regarding the efficacy and safety of the use of benzodiazepines amongst individuals with OABD is limited.\textsuperscript{42} Morishita and Aoki evaluated the use of clonazepam for 4 weeks amongst a mixed-age population of individuals with both unipolar depression (53.6±13.7 years) and bipolar depression (50.4±10.7 years).\textsuperscript{74} The investigators found that, amongst the bipolar depression group, only 10.5% (2/19 participants) of the individuals fulfilled the response criteria (80% reduction) on...
the HDRS when compared to 84.2% (16/19 participants, \( p < 0.05 \)) of the individuals in the unipolar depression group. Clonazepam was well tolerated as there were no side-effects noted amongst the study participants. In a retrospective chart review, Winkler et al. also included older individuals (56.3±16.5 years) with BD who were treated with clonazepam either as monotherapy or as adjunctive therapy to lithium for individuals who did not respond to lithium.\(^7\) The investigators found that individuals with BD did not have any benefit from the use of clonazepam for either their manic or hypomanic episodes nor for their depressive episodes. However, the individuals with unipolar depression had less depressive episodes after treatment with clonazepam (\( p = 0.026 \)).\(^7\)

**Electroconvulsive therapy**

Amongst individuals with BD, ECT remains the definitive treatment when there is a need for rapid and significant clinical improvements.\(^5\) ECT is particularly effective amongst individuals with BD who present with imminent suicide risk, homicide risk, catatonic state, refractory psychotic state, agitated state or a medically unstable condition.\(^6,7\) ECT has been noted to be effective in approximately 80% of the cases with BD.\(^7,8\) Controlled studies of ECT amongst older individuals with BD are still lacking.\(^7,8\) In clinical situations where symptoms are unresponsive to pharmacotherapy or where a quick and significant response to treatment is required, ECT remains the treatment modality of choice amongst individuals with OABD.\(^7,8\) Amongst individuals with depression, available evidence indicates equal efficacy for both right unilateral and bilateral treatments.\(^8,9\) However, bilateral treatments are associated with longer postictal recovery time and greater impairments in memory.

**Treatment algorithm**

Current evidence does not include any specialized algorithm for the treatment of individuals with OABD.\(^5\) Evidence suggests that the initial trial of medication for individuals with OABD should be of at least 3–4 weeks duration.\(^3\) A judicious combination of medications should be considered if monotherapy does not provide the desired results. For individuals with OABD who have responded adequately to a medication or a combination of medications, these agents should be continued for a period of approximately 6–12 months. For those individuals in whom the symptoms are in remission for a period of at least 12 months, a gradual reduction and discontinuation of adjunctive medications could be attempted.\(^7\) Available evidence indicates that, amongst individuals with OABD, the use of combination medications is very common, with one study indicating that approximately 82% of these individuals have two or more psychotropic medications prescribed.\(^9\) In this study, which included 1443 individuals aged \( \geq 66 \) years who were discharged from a psychiatric hospital and information on psychotropic medications prescribed within 30 days of discharge was available, the most common medications were atypical antipsychotics (75.3%) followed by benzodiazepines/zopiclone (42.3%) and antidepressants (38.5%). VPA (35.4%) and lithium (23.4%) appeared to be used less commonly amongst these individuals. Surprisingly, only 1.4% of these individuals were treated using lithium monotherapy. Additionally, only 4.4% and 15.7% of individuals were prescribed antidepressant or atypical antipsychotic monotherapy, respectively. About 8.9% of individuals were prescribed two or more atypical antipsychotics. It has been noted that only about 1 in 10 individuals with OABD experience sustained clinical improvements with standard treatment strategies.\(^8,10\) Poor adherence to pharmacotherapy, comorbid substance use disorders and co-occurring neurological illnesses have been found to reduce the responsiveness to treatment amongst people with OABD.\(^6\) In addition, pre-existing levels of psychosocial functioning, residential status and occupational position affect the functional outcomes amongst these individuals.\(^5\)

An algorithm for the treatment of bipolar disorder amongst older adults is provided in Table 2.

**Conclusions**

OABD is not an uncommon condition. Available evidence indicates that individuals with OABD have more comorbid

---

**Table 2. Proposed algorithm for the treatment of older-age bipolar disorder.**\(^3,8,9,40–79\)

| Type of mood episode | Medication/medication class | Additional information |
|----------------------|----------------------------|------------------------|
| Manic episodes       | Lithium                    | Better for:            |
|                      |                            | 1. Manic episode       |
|                      |                            | 2. Depressive episode  |
|                      |                            | 3. Maintenance treatment |
|                      |                            | Dose: 25–50% of adult dose |
|                      |                            | Recommended level: 0.4–0.7 mEq/L |
|                      |                            | Tolerability: less than amongst younger individuals |

(Continued)
Although there is a scarcity of controlled pharmacotherapy trials for the treatment of individuals with OABD, available evidence from mixed age population studies indicates the efficacy for commonly used medication classes that are used in the treatment of individuals with EOBD. Individuals with OABD also find psychosocial treatments to be beneficial as adjunctive treatments. Evidence indicates that ECT is often an effective treatment for refractory cases. There is a significant need to evaluate the effect of underlying medical/neurological disorders, prescribed medication or substances of abuse, as they may precipitate or perpetuate symptoms of OABD.

Table 2. (Continued)

| Type of mood episode | Medication/medication class | Additional information |
|----------------------|-----------------------------|-----------------------|
| **Manic episodes**   | Anticonvulsant mood stabilizers | Better for:  
1. Mixed episodes  
2. Rapid cyclers  
3. Individuals with medical and psychiatric comorbidities  
4. Maintenance treatment  
Dose: 25–50% of adult dose  
Tolerability: less than amongst younger individuals |
| **Atypical antipsychotics** | | Better for:  
1. Manic episode  
2. Maintenance treatment  
Dose: 25–50% of adult dose  
Tolerability:  
1. Less than amongst younger individuals  
2. Metabolic syndrome with prolonged use  
3. Higher risk of cerebrovascular events and death amongst individuals with dementia |
| **Depressive episode** | Lithium | As above |
| Anticonvulsant mood stabilizers | | Lamotrigine appears to be better for bipolar depression than mania |
| Atypical antipsychotics | Quetiapine extended release and lurasidone are FDA approved for bipolar depression; olanzapine–fluoxetine combination is also FDA approved for bipolar depression |
| **Partial response or refractory cases** | Electroconvulsive therapy | Beneficial for individuals with refractory psychotic or catatonic symptoms  
Efficacy: bilateral = unilateral  
Tolerability:  
1. Less than amongst younger individuals  
2. Side-effect are bilateral > unilateral |
| **Adjunctive treatments** | Benzodiazepines | Adjunct treatment for manic or hypomanic episodes  
Dose: 25–50% of adult dose  
Tolerability:  
1. Less than amongst younger individuals  
2. High risk of cognitive and functional impairments |
| Psychosocial therapies | | Adjunctive treatment to medications  
Tolerability: as well as amongst younger individuals |
have a better understanding of the phenomenology and neurobiology of OABD. In addition, more research into effective treatments for this serious psychiatric disorder amongst older adults is needed. Effective treatments will mitigate the suffering of individuals with OABD and reduce the morbidity and mortality of this condition.

Contributions: RRT did the literature search for this narrative review. All the authors contributed equally to the conceptualization, reviewing of the data, writing and editing of this manuscript.

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript.

The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/05/dic.2021-1-8-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2021 Tampi RR, Joshi P, Bhattacharya G, Gupta S. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Tampi RR, Joshi P, Bhattacharya G, Gupta S. https://doi.org/10.7573/dic.2021-1-8. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/evaluation-and-treatment-of-older-age-bipolar-disorder:-a-narrative-review

Correspondence: Rajesh R Tampi, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Akron, Ohio, 44307, USA. Email: rajesh.tampi@gmail.com

Provenance: Invited; externally peer reviewed.

Submitted: 29 January 2021; Accepted: 26 April 2021; Publication date: 27 May 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

References

1. Bipolar and Related Disorders. In: Diagnostic and Statistical Manual of Mental Disorders. DSM Library. American Psychiatric Association; 2013. https://doi.org/10.1176/appi.books.9780890425596.dsm03

2. Montes JM, Alegría A, García-López A, et al. Understanding bipolar disorder in late life: clinical and treatment correlates of a sample of elderly outpatients. J Nerv Ment Dis. 2013;201(8):674–679. https://doi.org/10.1097/NMD.0b013e318295c08d

3. Dols A, Beekman A. Older age bipolar disorder. Clin Geriatr Med. 2020;36(2):281–296. https://doi.org/10.1016/j.cger.2019.11.008

4. Almeida OP, Fenner S. Bipolar disorder: similarities and differences between patients with illness onset before and after 65 years of age. Int Psychogeriatr. 2002;14(3):311–322. https://doi.org/10.1017/s1041610202008517

5. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647. https://doi.org/10.1136/bmj.g7647

6. Sajatovic M, Strejilevich SA, Gildengers AG, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17(7):689–704. https://doi.org/10.1111/bdi.12331

7. Sajatovic M, Blow FC, Ignacio RV, Kales HC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr Serv. 2004;55(9):1014–1021. https://doi.org/10.1176/appi.ps.55.9.1014

8. Sajatovic M, Chen P. Geriatric bipolar disorder. Psychiatr Clin North Am. 2011;34(2):319–333. https://doi.org/10.1016/j.psc.2011.02.007

9. Depp CA, Jin H, Mohamed S, Kaskow J, Moore DJ, Jeste DV. Bipolar disorder in middle-aged and elderly adults: is age of onset important? J Nerv Ment Dis. 2004;192(11):796–799. https://doi.org/10.1097/01.nmd.0000145055.45944.d6

10. Yassa R, Nair V, Nastase C, Camille Y, Belzile L. Prevalence of bipolar disorder in a psychogeriatric population. J Affect Disord. 1988;14(3):197–201. https://doi.org/10.1016/0165-0327(88)90035-3

11. Depp CA, Jeste DV. Bipolar disorder in older adults: a critical review. Bipolar Disord. 2004;6(5):343–367. https://doi.org/10.1111/j.1399-5618.2004.00139.x
12. Stone K. Mania in the elderly. *Br J Psychiatry*. 1989;155:220–224. https://doi.org/10.1192/bjp.155.2.220

13. Shulman KJ, Tohen M, Satlin A, Mallya G, Kalunian D. Mania compared with unipolar depression in old age. *Am J Psychiatry*. 1992;149(3):341–345. https://doi.org/10.1176/ajp.149.3.341

14. Tohen M, Shulman KJ, Satlin A. First-episode mania in late life. *Am J Psychiatry*. 1994;151(1):130–132. https://doi.org/10.1176/ajp.151.1.130

15. García-López A, Ezquiaga E, De Dios C, Agud JL. Depressive symptoms in early- and late-onset older bipolar patients compared with younger ones. *Int J Geriatr Psychiatry*. 2017;32(2):201–207. https://doi.org/10.1002/gps.4465

16. Hays JC, Krishnan KR, George LK, Blazer DG. Age of first onset of bipolar disorder: demographic, family history, and psychosocial correlates. *Depress Anxiety*. 1998;7(2):76–82.

17. Beyer JL, Kuchibhatla M, Cassidy F, Krishnan KRR. Stressful life events in older bipolar patients. *Int J Geriatr Psychiatry*. 2008;23(12):1271–1275. https://doi.org/10.1002/gps.2062

18. Robinson RG, Starkstein SE. Current research in affective disorders following stroke. *J Neuropsychiatry Clin Neurosci*. 1990;2(1):1–14. https://doi.org/10.1176/jnp.2.1.1

19. Steffens DC, Krishnan KR. Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. *Biol Psychiatry*. 1998;43(10):705–712. https://doi.org/10.1016/s0006-3223(98)00084-5

20. Gildengers AG, Whyte EM, Drayer RA, et al. Medical burden in late-life bipolar and major depressive disorders. *Am J Geriatr Psychiatry*. 2008;16(3):194–200. https://doi.org/10.1097/JGP.0b013e318157c5b1

21. Kilbourne AM, Post EP, Nossek A, Drill L, Cooley S, Bauer MS. Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. *Psychiatr Serv*. 2008;59(7):760–768. https://doi.org/10.1176/ps.2008.59.7.760

22. Mcintyre RS, Konarski JZ, Szoczenska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. *Psychiatr Serv*. 2006;57(8):1140–1144. https://doi.org/10.1176/ps.2006.57.8.1140

23. Juurlink DN, Herrmann N, Szalai JP, Kopp A, Redelmeier DA. Medical illness and the risk of suicide in the elderly. *Arch Intern Med*. 2004;164(11):1179–1184. https://doi.org/10.1001/archinte.164.11.1179

24. Subramaniam H, Dennis MS, Byrne EJ. The role of vascular risk factors in late onset bipolar disorder. *Int J Geriatr Psychiatry*. 2007;22(8):733–737. https://doi.org/10.1002/gps.1730

25. Lloyd AJ, Moore PB, Cousins DA, et al. White matter lesions in euthymic patients with bipolar disorder. *Acta Psychiatr Scand*. 2009;120(6):481–491. https://doi.org/10.1111/j.1600-0447.2009.01416.x

26. Tamashiro JH, Zung S, Zanetti MV, et al. Increased rates of white matter hyperintensities in late-onset bipolar disorder. *Biol Psychiatry*. 2008;10(7):765–775. https://doi.org/10.1016/j.biopsych.2008.06.021.x

27. Sarnicola A, Kempton M, Germanà C, et al. No differential effect of age on brain matter volume and cognition in bipolar patients and healthy individuals. *Bipolar Disord*. 2009;11(3):316–322. https://doi.org/10.1111/j.1399-5618.2009.00670.x

28. Young RC, Nambudiri DE, Jain H, de Asis JM, Alexopoulos GS. Brain computed tomography in geriatric manic disorder. *Biol Psychiatry*. 1999;45(8):1063–1065. https://doi.org/10.1016/s0006-3223(98)00201-7

29. Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. *Am J Psychiatry*. 2006;163(2):319–321. https://doi.org/10.1176/appi.ajp.163.2.319

30. Okolie C, Dennis M, Simon Thomas E, John A. Age of first onset of bipolar disorder: a systematic review of the recent global literature. *Bipolar Disord*. 2018;20(4):359–369. https://doi.org/10.1111/bid.12566

31. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. *Am J Psychiatry*. 2000;157(11):1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873

32. Zimmerman M, Ruggero CJ, Gallone JN, et al. Detecting differences in diagnostic assessment of bipolar disorder. *J Nerv Ment Dis*. 2010;198(5):339–342. https://doi.org/10.1097/NMD.0b013e3181d44f67

33. Baldassano CF. Assessment tools for screening and monitoring bipolar disorder. *Bipolar Disord*. 2005;7(Suppl. 1):8–15. https://doi.org/10.1111/j.1399-5618.2005.00189.x
40. Depp CA, Lebowitz BD, Patterson TL, Lacro JP, Jeste DV. Medication adherence skills training for middle-aged and elderly adults with bipolar disorder: development and pilot study. Bipolar Disord. 2007;9(6):636–645. https://doi.org/10.1111/j.1399-5618.2007.00397.x

41. Kilbourne AM, Post EP, Nossek A, et al. Service delivery in older patients with bipolar disorder: a review and development of a medical care model. Bipolar Disord. 2008;10(6):672–683. https://doi.org/10.1111/j.1399-5618.2008.00602.x

42. Aziz R, Lorberg B, Tampi RR. Treatments for late-life bipolar disorder. Am J Geriatr Pharmacother. 2006;4(4):347–364. https://doi.org/10.1016/j.amjopharm.2006.12.007

43. Dols A, Kessing LV, Strejilevich SA, et al. Do current national and international guidelines have specific recommendations for older adults with bipolar disorder? A brief report. Int J Geriatr Psychiatry. 2016;31(12):1295–1300. https://doi.org/10.1002/gps.4534

44. Fotso Soh J, Kili-Droi S, Rej S. Using lithium in older age bipolar disorder: special considerations. Drugs Aging. 2019;36(2):147–154. https://doi.org/10.1007/s40266-018-0628-1

45. Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging. 2005;22(1):39–54. https://doi.org/10.2165/00002512-200522010-00003

46. Sajatovic M. Treatment of bipolar disorder in older adults. Int J Geriatr Psychiatry. 2002;17(9):865–873. https://doi.org/10.1002/gps.719

47. Kessing LV, Sendergård L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry. 2005;62(8):860–866. https://doi.org/10.1001/archpsyc.62.8.860

48. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12(1):87–94. https://doi.org/10.1111/j.1399-5618.2009.00778.x

49. Shulman KI, Almeida OP, Herrmann N, et al. Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD task force report. Bipolar Disord. 2019;21(2):117–123. https://doi.org/10.1111/bdi.12714

50. Eastham JH, Jeste DV, Young RC. Assessment and treatment of bipolar disorder in the elderly. Drugs Aging. 1998;12(3):205–224. https://doi.org/10.2165/00002512-199812030-00004

51. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(Suppl. 4):1–50.

52. Shulman KI, Rochon P, Szykora K, et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ. 2003;326(7396):960–961. https://doi.org/10.1136/bmj.326.7396.960

53. Miklowitz DJ. A review of evidence-based psychosocial interventions for bipolar disorder. J Clin Psychiatry. 2006;67 (Suppl. 11):28–33.

54. Chen ST, Altshuler LL, Melnyk KA, Erhart SM, Miller E, Mintz J. Efficacy of lithium vs. valproate in the treatment of mania in the elderly adults with bipolar disorder. J Clin Psychiatry. 2009;70(4):431–437. https://doi.org/10.4088/jcp.v70n0406

55. Schneider AL, Wilcox CS. Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. J Affect Disord. 1998;47(1–3):201–205. https://doi.org/10.1016/s0165-0327(97)00157-2

56. Goldberg JF, Sacks MH, Kocsis JH. Low-dose lithium augmentation of divalproex in geriatric mania. J Clin Psychiatry. 2000;61(4):304. https://doi.org/10.4088/jcp.v61n0410h

57. Young RC, Mulsant BH, Sajatovic M, et al. GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017;174(11):1086–1093. https://doi.org/10.1176/appi.ajp.2017.15050657

58. Sajatovic M, Gyulai L, Calabrese JR, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry. 2005;13(4):305–311. https://doi.org/10.1168/ajjp.13.4.305

59. Depp CA, Davis CE, Mittal D, Patterson TL, Jeste DV. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry. 2006;67(2):215–221. https://doi.org/10.4088/jcp.v67n0207

60. Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998;18(6):455–460. https://doi.org/10.1097/00004714-199812000-00007

61. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl). 2000;150(1):15–23. https://doi.org/10.1007/s002130000380

62. Atypical Antipsychotics Medications: Use in Adults. https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/atyp-antipsych-adult-factsheet11-14.pdf. Accessed December 3, 2020.

63. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013;18(Suppl. 1):4–20; quiz 21. https://doi.org/10.1017/S1092852913000746

64. Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry. 1995;56(11):514–518.
65. Shulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. *Psychopharmacol Bull.* 1997;33(1):113–118.

66. Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. *Bipolar Disord.* 2008;10(6):662–671. [https://doi.org/10.1111/j.1399-5618.2008.00614.x](https://doi.org/10.1111/j.1399-5618.2008.00614.x)

67. Baruch Y, Tadger S, Plopski I, Barak Y. Asenapine for elderly bipolar manic patients. *J Affect Disord.* 2013;145(1):130–132. [https://doi.org/10.1016/j.jad.2012.05.027](https://doi.org/10.1016/j.jad.2012.05.027)

68. Sajatovic M, Dines P, Fuentes-Casiano E, et al. Asenapine in the treatment of older adults with bipolar disorder. *Int J Geriatr Psychiatry.* 2015;30(7):710–719. [https://doi.org/10.1002/gps.4213](https://doi.org/10.1002/gps.4213)

69. Sajatovic M, Forester BP, Tsai J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. *J Clin Psychiatry.* 2016;77(10):e1324–e1331. [https://doi.org/10.4088/JCP.15m10261](https://doi.org/10.4088/JCP.15m10261)

70. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry.* 2014;171(2):160–168. [https://doi.org/10.1176/appi.ajp.2013.13070984](https://doi.org/10.1176/appi.ajp.2013.13070984)

71. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry.* 2014;171(2):169–177. [https://doi.org/10.1176/appi.ajp.2013.13070985](https://doi.org/10.1176/appi.ajp.2013.13070985)

72. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. *Am J Alzheimers Dis Other Demen.* 2011;26(1):10–28. [https://doi.org/10.1177/1533317510390351](https://doi.org/10.1177/1533317510390351)

73. Schaffer A, Mamdani M, Levitt A, Herrmann N. Effect of antidepressant use on admissions to hospital among elderly bipolar patients. *Int J Geriatr Psychiatry.* 2006;21(3):275–280. [https://doi.org/10.1002/gps.1460](https://doi.org/10.1002/gps.1460)

74. Morishita S, Aoki S. Clonazepam augmentation of antidepressants: does it distinguish unipolar from bipolar depression? *J Affect Disord.* 2002;71(1–3):217–220. [https://doi.org/10.1016/s0165-0327(01)00358-5](https://doi.org/10.1016/s0165-0327(01)00358-5)

75. Winkler D, Willeit M, Wolf R, et al. Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. *Eur Neuropsychopharmacol.* 2003;13(2):129–134. [https://doi.org/10.1016/s0924-977x(02)00174-8](https://doi.org/10.1016/s0924-977x(02)00174-8)

76. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years’ experience. *Am J Psychiatry.* 1994;151(2):169–176. [https://doi.org/10.1176/ajp.151.2.169](https://doi.org/10.1176/ajp.151.2.169)

77. McDonald WM. Neuromodulation treatments for geriatric mood and cognitive disorders. *Am J Geriatr Psychiatry.* 2016;24(12):1130–1141. [https://doi.org/10.1016/j.jagp.2016.08.014](https://doi.org/10.1016/j.jagp.2016.08.014)

78. Young RC, Gyulai L, Mulsant BH, et al. Pharmacotherapy of bipolar disorder in old age: review and recommendations. *Am J Geriatr Psychiatry.* 2004;12(4):342–357. [https://doi.org/10.1016/j.jagp.2012.04.342](https://doi.org/10.1016/j.jagp.2012.04.342)

79. Fraser RM, Glass IB. Unilateral and bilateral ECT in elderly patients. A comparative study. *Acta Psychiatr Scand.* 1980;62(1):13–31. [https://doi.org/10.1111/j.1600-0447.1980.tb00590.x](https://doi.org/10.1111/j.1600-0447.1980.tb00590.x)

80. Rej S, Herrmann N, Shulman K, Fischer HD, Fung K, Gruneir A. Current psychotropic medication prescribing patterns in late-life bipolar disorder. *Int J Geriatr Psychiatry.* 2017;32(12):1459–1465. [https://doi.org/10.1002/gps.4635](https://doi.org/10.1002/gps.4635)

81. Gildengers AG, Mulsant BH, Begley AE, et al. A pilot study of standardized treatment in geriatric bipolar disorder. *Am J Geriatr Psychiatry.* 2005;13(4):319–323. [https://doi.org/10.1176/appi.ajgp.13.4.319](https://doi.org/10.1176/appi.ajgp.13.4.319)